Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2019-02-26 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing results from a new analysis of pooled clinical data on an investigational pharmaceutical product, Ryaltris, presented at a medical conference (AAAAI 2019 Annual Meeting). It is addressed to stock exchanges and is a media release rather than a financial or regulatory report. There are no financial statements, regulatory certifications, or detailed management discussions. The content focuses on clinical trial results and product pipeline updates, typical of a press release or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. Given the nature and content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2019-02-26 English
Press Release
Investor Presentation Classification · 95% confidence The document is a press release announcing Glenmark Pharmaceuticals' presentation of new pooled data analysis on an investigational product at a medical conference (AAAAI 2019 Annual Meeting). It is not a financial report, regulatory filing, or management announcement. The content focuses on clinical trial data presentation and product pipeline updates, typical of a media or investor announcement. There is no financial data, no regulatory compliance content, no voting or shareholder meeting information, and no detailed financial or management discussion. Therefore, it fits best as an Investor Presentation (IP) type document, as it is a detailed presentation for investors and the public focusing on product development and clinical data relevant to the company's market position and strategy.
2019-02-20 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific pharmaceutical product. It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a media release about regulatory approval, not a financial report, earnings release, or management discussion. The document length is short (3799 characters) and it is clearly an announcement of an event rather than a detailed report or filing. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-02-18 English
Financial Result Updates
Regulatory Filings
2019-02-14 English
Outcome of Board Meeting
Regulatory Filings
2019-02-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for specific pharmaceutical products. It is addressed to stock exchanges and includes a media release. There is no financial data, no detailed report, no management discussion, or regulatory filing content. The document is a corporate announcement about a regulatory approval event, not a financial report or detailed filing. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance document. It is also not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and corporate disclosures that do not fit other categories.
2019-02-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.